What is Giiant Pharma?
Giiant Pharma is at the forefront of developing specialized gut-restricted, small molecule therapeutics designed to combat inflammatory bowel diseases (IBD). The company's core innovation lies in its precision delivery technology, which ensures that therapeutic agents are released directly within the lower gastrointestinal tract. This targeted approach minimizes systemic exposure, thereby enhancing drug tolerability and patient care. By leveraging the gut microbiota for drug bioactivation, Giiant Pharma aims to provide safer, more effective, and patient-tailored treatments for a range of gastrointestinal conditions, positioning itself as a leader in precision delivery solutions.
How much funding has Giiant Pharma raised?
Giiant Pharma has raised a total of $12.3M across 2 funding rounds:
Angel/Seed
$11M
Angel/Seed
$1.3M
Angel/Seed (2021): $11M with participation from Genesys Capital, Anges Québec, Fonds de Solidarité FTQ, AmorChem, Amplitude Ventures, and Theodorus Investment Funds
Angel/Seed (2021): $1.3M led by Amplitude Ventures and Genesys Capital
Key Investors in Giiant Pharma
Amplitude Ventures
Amplitude Ventures is a venture capital firm focused on building and scaling Canadian precision medicine companies, deploying a growth model with offices in Montreal, Toronto, and Vancouver.
Genesys Capital
Genesys Capital is a Toronto-based venture capital firm that invests in early-stage life sciences and healthcare companies, focusing on biotechnology and medical innovation across North America.
Anges Québec
Anges Québec is a prominent network of angel investors in Canada that supports innovative projects by providing capital and strategic guidance to technology entrepreneurs.
What's next for Giiant Pharma?
The substantial enterprise-level backing Giiant Pharma has received, particularly the recent strategic investment, indicates a pivotal stage for the company's growth and development. This capital infusion is expected to accelerate the advancement of its pipeline, potentially enabling further clinical trials, expanding its research and development capabilities, and solidifying its market position in the competitive landscape of gastrointestinal therapeutics. The strategic nature of the recent financing suggests a focus on scaling operations and potentially forging key partnerships to bring its innovative therapies to patients.
See full Giiant Pharma company page
